Difference between revisions of "Team:Tuebingen/landingAni2"

 
Line 10,366: Line 10,366:
 
     <div class="row pt-5 pb-3 ">
 
     <div class="row pt-5 pb-3 ">
 
         <div class="warningContent col-12">
 
         <div class="warningContent col-12">
−
             <span class="align-middle">GLP.exe - a cheap and safe treatment for diabetes mellitus type 2</span>
+
             <span class="align-middle">GLP.exe - a safe and effective treatment for Diabetes Mellitus Type II</span>
 
         </div>
 
         </div>
 
     </div>
 
     </div>
Line 10,376: Line 10,376:
 
         </div>
 
         </div>
 
         <div class="col-12 col-md-6 pt-3" style="padding-right: 6vw;">
 
         <div class="col-12 col-md-6 pt-3" style="padding-right: 6vw;">
−
             <p class="text-justify  mobileText">Several treatment options for type 2 diabetes mellitus
+
             <p class="text-justify  mobileText">Several treatment options for Type II Diabetes Mellitus
−
                 have been developed in recent years.
+
                 have been developed in recent years significantly improving the patients' insulin level.
 
             </p>
 
             </p>
  
 
             <p class="text-justify  mobileText">
 
             <p class="text-justify  mobileText">
−
                 Hence, the diagnosis of type 2 diabetes mellitus is no longer a death sentence.
+
                 Hence, the diagnosis of Type II Diabetes Mellitus is no longer a death sentence.
 
             </p>
 
             </p>
 
         </div>
 
         </div>
Line 10,389: Line 10,389:
 
     <div class="row pt-5 pb-3 ">
 
     <div class="row pt-5 pb-3 ">
 
         <div class="warningContent col-12 slide-in">
 
         <div class="warningContent col-12 slide-in">
−
             <span class="align-middle">yet...</span>
+
             <span class="align-middle">Yet...</span>
 
         </div>
 
         </div>
 
     </div>
 
     </div>
Line 10,408: Line 10,408:
 
         <div class="col-12 col-md-6 pt-3" style="padding-right: 6vw;">
 
         <div class="col-12 col-md-6 pt-3" style="padding-right: 6vw;">
 
             <h2 class="display-4 mobileTitle">Current Drugs</h2>
 
             <h2 class="display-4 mobileTitle">Current Drugs</h2>
−
             <p class="text-justify mobileText">...are expensive, require fine tuning and daily shots.
+
             <p class="text-justify mobileText">are expensive, require fine tuning and daily shots.
 
                 Moreover, they have severe side-effects, causing patients to skip doses.</p>
 
                 Moreover, they have severe side-effects, causing patients to skip doses.</p>
  
Line 10,514: Line 10,514:
  
 
         <div class="col-12 col-md-6 pt-3" style="padding-right: 6vw;">
 
         <div class="col-12 col-md-6 pt-3" style="padding-right: 6vw;">
−
             <h2 class="display-4 mobileTitle" style="overflow-x: visible">An in depth E.coli Nissle characterization.</h2>
+
             <h2 class="display-4 mobileTitle" style="overflow-x: visible">An in depth E.coli Nissle characterization</h2>
−
             <p class="text-justify mobileText">Despite the fact that E. Coli Nissle is an alreasdy
+
             <p class="text-justify mobileText">Despite the fact that E. Coli Nissle is an already
 
                 approved probiotic, it's surprisingly badly characterized.</p>
 
                 approved probiotic, it's surprisingly badly characterized.</p>
  
 
             <p class="text-justify mobileText">
 
             <p class="text-justify mobileText">
 
                 Hence, we provide the first metabolic model of E. coli Nissle and optimize it's growth for various
 
                 Hence, we provide the first metabolic model of E. coli Nissle and optimize it's growth for various
−
                 growth media. Furthermore, we predicted the interaction and competition of E. coli Nissle with common
+
                 growth media. Furthermore, we predicted the interaction and competition of E. coli Nissle with common competitors for various fluxes in the gut.
−
                competitors for various fluxes.
+
 
             </p>
 
             </p>
  
 
             <p class="text-justify mobileText">
 
             <p class="text-justify mobileText">
 
                 Finally, we carried out a series of RNA-Seq experiments to assess the adaptions and reactions of E. coli
 
                 Finally, we carried out a series of RNA-Seq experiments to assess the adaptions and reactions of E. coli
−
                 Nissle to aerob, as well as anaerob occuring stress factors.
+
                 Nissle to aerobic, as well as anaerobic occurring stress factors.
 
             </p>
 
             </p>
 
         </div>
 
         </div>
Line 10,554: Line 10,553:
  
 
         <div class="col-12 col-md-6 pt-3" style="padding-right: 6vw;">
 
         <div class="col-12 col-md-6 pt-3" style="padding-right: 6vw;">
−
             <h2 class="display-4 mobileTitle">Our work lays the foundation for an innovative, unprecedented approach to treat diabetes mellitus type 2.</h2>
+
             <h2 class="display-4 mobileTitle">Our work lays the foundation for an innovative, unprecedented approach to treat Diabetes Mellitus Type II.</h2>
 
         </div>
 
         </div>
 
     </div>
 
     </div>
Line 10,565: Line 10,564:
 
.testclasse {
 
.testclasse {
 
   margin: 0;
 
   margin: 0;
−
   background-color: #e12835;
+
   background-color: #2ecc71;
−
   background-image: radial-gradient(#e12835 20%, #be2633 50%, rgba(0, 0, 0, 0.5) 100%);
+
   background-image: radial-gradient(#2ecc71 20%, #1b7a43 50%, rgba(0, 0, 0, 0.5) 100%);
 
   background-size: 120%;
 
   background-size: 120%;
 
   background-position: center;
 
   background-position: center;
Line 10,643: Line 10,642:
 
   content: '';
 
   content: '';
 
   display: block;
 
   display: block;
−
   background-color: #e12835;
+
   background-color: #2ecc71;
 
   border: solid rgba(255, 255, 255, 0.2) 1px;
 
   border: solid rgba(255, 255, 255, 0.2) 1px;
 
   height: 100%;
 
   height: 100%;
Line 10,700: Line 10,699:
 
         font-size: 3rem;
 
         font-size: 3rem;
 
     }
 
     }
 +
}
 +
 +
.wrapper.run-animation .restart {
 +
  opacity: 0;
 +
  -webkit-animation: fade-down 1200ms ease 3600ms forwards;
 +
          animation: fade-down 1200ms ease 3600ms forwards;
 
}
 
}
  
Line 10,706: Line 10,711:
 
           animation: shrink ease-out 4800ms forwards 600ms;
 
           animation: shrink ease-out 4800ms forwards 600ms;
 
}
 
}
 +
 
.babbelbubu.run-animation .marvel {
 
.babbelbubu.run-animation .marvel {
 
   -webkit-transform: translateX(95px);
 
   -webkit-transform: translateX(95px);
Line 10,908: Line 10,914:
 
<div class="logo">
 
<div class="logo">
  
−
<span class="marvel" >Click For</span>
+
        <span class="marvel" > <a href="https://www.google.com" style="color: #fff;text-decoration: none;">View our</a></span>
−
<span class="studios" >Our Story</span>
+
<span class="studios" > <a href="https://www.google.com" style="color: #fff;text-decoration: none;">Story</a></span>
 +
 
 +
        <div class="restart">Restart</div>
  
−
<div class="restart"> <a href="www.google.com">CLICK ME</a></div>
 
 
         <div class="kokosnusss"></div>
 
         <div class="kokosnusss"></div>
 
</div>
 
</div>

Latest revision as of 20:57, 14 October 2019

GLP.exe

GLP.exe - a safe and effective treatment for Diabetes Mellitus Type II
meetUp

Several treatment options for Type II Diabetes Mellitus have been developed in recent years significantly improving the patients' insulin level.

Hence, the diagnosis of Type II Diabetes Mellitus is no longer a death sentence.

Yet...
meetUp

Current Drugs

are expensive, require fine tuning and daily shots. Moreover, they have severe side-effects, causing patients to skip doses.

“Many patients don’t want to use insulin. They don’t want to do finger sticks and they’re afraid of hypoglycemia.”

“To fight the global diabetes pandemic, we would ideally have an accessible cost-effective easily-compliant intervention that has high clinical efficacy and that is free of adverse side effects.”

Prof. Harold Lebovitz, State University of New York Health Science Center, Brooklyn, New York

However...
meetUp

There's a solution!

Our therapeutic agent is a probiotic secreting incretin mimetics placed in the patients intestine by oral administration of capsules. GLP-1 and Exendin-4, our main actors, cause an increase in insulin secretion, if the cell has already taken up sugar.

This enables an easier therapy where a regular intake of medicals are not required.

Improved cell penetrating peptides with the use of artificial intelligence allow for an efficient and safe transport of our effectors into the cells.

Safety
meetUp

is our highest priority!

Therefore, we developed a novel, Cas3 based kill-switch mechanism. The flexible system uses three regulators inspired by the human intestines: temperature, availability of fatty acids in form of Acyl CoA and N-Acetyl-Glucosamin.

If the conditions of our regulatory system are no longer met, Cas3 will be degrading all genetic information.

Additionally
meetUp

An in depth E.coli Nissle characterization

Despite the fact that E. Coli Nissle is an already approved probiotic, it's surprisingly badly characterized.

Hence, we provide the first metabolic model of E. coli Nissle and optimize it's growth for various growth media. Furthermore, we predicted the interaction and competition of E. coli Nissle with common competitors for various fluxes in the gut.

Finally, we carried out a series of RNA-Seq experiments to assess the adaptions and reactions of E. coli Nissle to aerobic, as well as anaerobic occurring stress factors.

Bringing it all together
meetUp

Our work lays the foundation for an innovative, unprecedented approach to treat Diabetes Mellitus Type II.